We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Epigenetic Variation May Be Responsible for Hereditary Disorders

By LabMedica International staff writers
Posted on 07 Jun 2018
Genomics researchers have suggested that some hereditary disorders are caused by epigenetic variation that modifies gene expression rather than by traditional mutation that changes the sequence of DNA bases.

Certain human traits such as neurodevelopmental disorders (NDs) and congenital anomalies (CAs) are believed to be primarily genetic in origin. More...
However, even after whole-genome sequencing (WGS), a substantial fraction of such disorders remain unexplained.

To solve this mystery, investigators at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) proposed that some cases of ND–CA were likely caused by aberrant DNA methylation leading to epigenetic variation (epivariation) that disrupted genome function.

To test this theory, the investigators compared DNA methylation profiles from 489 individuals with ND–CAs to 1534 samples from control subjects. In the May 25, 2018, online edition of the journal Nature Communications, they reported that epivariations frequently occurred in the human genome. De novo epivariations were significantly enriched in ND-CA cases, while RNAseq analysis showed that epivariations often had an impact on gene expression comparable to loss-of-function mutations.

"Our study suggests that these epigenetic mutations are a significant contributor to human disease," said senior author Dr. Andrew Sharp, associate professor of genetic and genomic sciences at the Icahn School of Medicine. "These findings can open up a whole new world in what we know about disease and genetic profiling. Investigating DNA methylation when profiling genomes for disease mutations could help us uncover causative defects in congenital and neurodevelopmental diseases that have eluded us for years."

Related Links:
Icahn School of Medicine at Mount Sinai


Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
8-Channel Pipette
SAPPHIRE 20–300 µL
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.